Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Lung Cancer

  Free Subscription


11.06.2018

1 Am J Respir Crit Care Med
1 BMC Cancer
3 Clin Lung Cancer
1 Epidemiology
1 J Cancer Res Clin Oncol
2 J Clin Oncol
1 Lancet Oncol
8 Lung Cancer
1 N Engl J Med
1 Oncogene
1 Oncol Rep
1 PLoS One
1 Proc Natl Acad Sci U S A


  Retrieve available abstracts of this week’s articles:
HTML format
Text format
 
 
Single Articles


    Am J Respir Crit Care Med

  1. TSAY JJ, Wu BG, Badri MH, Clemente JC, et al
    Airway Microbiota Is Associated with Up-Regulation of the PI3K Pathway in Lung Cancer.
    Am J Respir Crit Care Med. 2018 Jun 4. doi: 10.1164/rccm.201710-2118.
    PubMed     Text format     Abstract available


    BMC Cancer

  2. ZHU H, Zhang S
    Body mass index and lung cancer risk in never smokers: a meta-analysis.
    BMC Cancer. 2018;18:635.
    PubMed     Text format     Abstract available


    Clin Lung Cancer

  3. FARRELL MJ, Yahya JB, Degnin C, Chen Y, et al
    Timing of Thoracic Radiation Therapy With Chemotherapy in Limited-stage Small-cell Lung Cancer: Survey of US Radiation Oncologists on Current Practice Patterns.
    Clin Lung Cancer. 2018 May 5. pii: S1525-7304(18)30089.
    PubMed     Text format     Abstract available

  4. OKUMA Y, Wakui H, Utsumi H, Sagawa Y, et al
    Soluble Programmed Cell Death Ligand 1 as a Novel Biomarker for Nivolumab Therapy for Non-Small-cell Lung Cancer.
    Clin Lung Cancer. 2018 May 5. pii: S1525-7304(18)30096.
    PubMed     Text format     Abstract available

  5. KOGURE Y, Saka H, Takiguchi Y, Atagi S, et al
    A Randomized Phase III Study Comparing Carboplatin With Nab-Paclitaxel Versus Docetaxel for Elderly Patients With Squamous-Cell Lung Cancer: Study Protocol.
    Clin Lung Cancer. 2018 May 19. pii: S1525-7304(18)30110.
    PubMed     Text format     Abstract available


    Epidemiology

  6. KEIL AP, Richardson DB, Westreich D, Steenland K, et al
    Estimating the impact of changes to occupational standards for silica exposure on lung cancer mortality.
    Epidemiology. 2018 Jun 4. doi: 10.1097/EDE.0000000000000867.
    PubMed     Text format     Abstract available


    J Cancer Res Clin Oncol

  7. OKUMA Y, Kashima J, Watanabe K, Homma S, et al
    Survival analysis and pathological features of advanced non-small cell lung cancer with miliary pulmonary metastases in patients harboring epidermal growth factor receptor mutations.
    J Cancer Res Clin Oncol. 2018 Jun 1. pii: 10.1007/s00432-018-2681.
    PubMed     Text format     Abstract available


    J Clin Oncol

  8. MOK TS, Cheng Y, Zhou X, Lee KH, et al
    Improvement in Overall Survival in a Randomized Study That Compared Dacomitinib With Gefitinib in Patients With Advanced Non-Small-Cell Lung Cancer and EGFR-Activating Mutations.
    J Clin Oncol. 2018 Jun 4:JCO2018787994. doi: 10.1200/JCO.2018.78.7994.
    PubMed     Text format     Abstract available

  9. PIOTROWSKA Z, Gainor JF
    ARCHER 1050: Hitting an Important Mark in EGFR-Mutant Lung Cancer?
    J Clin Oncol. 2018 Jun 4:JCO2018793059. doi: 10.1200/JCO.2018.79.3059.
    PubMed     Text format    


    Lancet Oncol

  10. GOURD E
    Lung cancer incidence higher in US women than men.
    Lancet Oncol. 2018 Jun 1. pii: S1470-2045(18)30422.
    PubMed     Text format    


    Lung Cancer

  11. YANG M, Tong X, Xu X, Zheng E, et al
    Case Report: Osimertinib achieved remarkable and sustained disease control in an advanced non-small-cell lung cancer harboring EGFR H773L/V774M mutation complex.
    Lung Cancer. 2018;121:1-4.
    PubMed     Text format     Abstract available

  12. TOPKAN E, Selek U, Ozdemir Y, Yildirim BA, et al
    Chemoradiotherapy-induced hemoglobin nadir values and survival in patients with stage III non-small cell lung cancer.
    Lung Cancer. 2018;121:30-36.
    PubMed     Text format     Abstract available

  13. NISHIO M, Nakagawa K, Mitsudomi T, Yamamoto N, et al
    Analysis of central nervous system efficacy in the J-ALEX study of alectinib versus crizotinib in ALK-positive non-small-cell lung cancer.
    Lung Cancer. 2018;121:37-40.
    PubMed     Text format     Abstract available

  14. KUIJPERS CCHJ, Hendriks LEL, Derks JL, Dingemans AC, et al
    Association of molecular status and metastatic organs at diagnosis in patients with stage IV non-squamous non-small cell lung cancer.
    Lung Cancer. 2018;121:76-81.
    PubMed     Text format     Abstract available

  15. TOMONAGA Y, Ten Haaf K, Frauenfelder T, Kohler M, et al
    Cost-effectiveness of low-dose CT screening for lung cancer in a European country with high prevalence of smoking-A modelling study.
    Lung Cancer. 2018;121:61-69.
    PubMed     Text format     Abstract available

  16. XIE F, Zhang Y, Mao X, Zheng X, et al
    Comparison of genetic profiles among primary lung tumor, metastatic lymph nodes and circulating tumor DNA in treatment-naive advanced non-squamous non-small cell lung cancer patients.
    Lung Cancer. 2018;121:54-60.
    PubMed     Text format     Abstract available

  17. NIE K, Zhang Z, Zhang C, Geng C, et al
    Osimertinib compared docetaxel-bevacizumab as third-line treatment in EGFR T790M mutated non-small-cell lung cancer.
    Lung Cancer. 2018;121:5-11.
    PubMed     Text format     Abstract available

  18. KOBAYASHI H, Naito T, Omae K, Omori S, et al
    ILD-NSCLC-GAP index scoring and staging system for patients with non-small cell lung cancer and interstitial lung disease.
    Lung Cancer. 2018;121:48-53.
    PubMed     Text format     Abstract available


    N Engl J Med

  19. ELMORE SNC
    p53 and Me.
    N Engl J Med. 2018;378:1962-1963.
    PubMed     Text format    


    Oncogene

  20. WANG K, Ji W, Yu Y, Li Z, et al
    FGFR1-ERK1/2-SOX2 axis promotes cell proliferation, epithelial-mesenchymal transition, and metastasis in FGFR1-amplified lung cancer.
    Oncogene. 2018 Jun 1. pii: 10.1038/s41388-018-0311.
    PubMed     Text format     Abstract available


    Oncol Rep

  21. LI Y, Wang C, Li D, Deng P, et al
    1H-NMR-based metabolic profiling of a colorectal cancer CT-26 lung metastasis model in mice.
    Oncol Rep. 2017 Sep 13. doi: 10.3892/or.2017.5954.
    PubMed     Text format     Abstract available


    PLoS One

  22. SILVA MA, Ryall KA, Wilm C, Caldara J, et al
    PD-L1 immunostaining scoring for non-small cell lung cancer based on immunosurveillance parameters.
    PLoS One. 2018;13:e0196464.
    PubMed     Text format     Abstract available


    Proc Natl Acad Sci U S A

  23. DE SEMIR D, Bezrookove V, Nosrati M, Dar AA, et al
    PHIP as a therapeutic target for driver-negative subtypes of melanoma, breast, and lung cancer.
    Proc Natl Acad Sci U S A. 2018 Jun 4. pii: 1804779115.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Lung Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: